Zydus Partners With Lupin To Launch its Weight Loss Injection in India

Zydus has partnered with Lupin to launch its weight loss injection in India, marking a major step in expanding access to semaglutide in India for both diabetes and obesity treatment.

The agreement allows Lupin to co-market Zydus’ semaglutide injection, helping the drug reach patients faster across the country.

The Zydus weight loss injection is based on semaglutide, a widely used molecule for managing type 2 diabetes and aiding weight loss. With patents nearing expiry, Indian pharmaceutical companies are moving quickly to introduce more affordable versions. This partnership gives Lupin semi-exclusive rights to distribute the drug, strengthening its presence in the fast-growing obesity treatment market in India.

Also Read: Advancing Interventional Radiology in India Through Collaboration

The injection will be offered through a reusable pen device, designed to improve convenience and long-term use. The companies aim to make the therapy more accessible compared to imported brands, which are often expensive for Indian patients. Rising cases of obesity and diabetes have created strong demand for effective treatments like semaglutide.

Industry experts see this move as the beginning of increased competition in the semaglutide injection market in India, which could drive down prices and improve availability. Zydus brings manufacturing strength, while Lupin adds a wide distribution network, making the collaboration strategically significant.

The launch is expected soon, positioning both companies to tap into a rapidly expanding segment. As more players enter the space, patients may benefit from better pricing and wider access to advanced therapies.